Genmab and AbbVie’s bispecific antibody met its primary endpoint in a head-to-head comparison, positioning the CD3xCD20 therapy for …
Genmab and AbbVie’s bispecific antibody met its primary endpoint in a head-to-head comparison, positioning the CD3xCD20 therapy for …
The approval of efanesoctocog alfa brings an extended half-life factor VIII replacement to the Australian market, arriving as …
The bispecific antibody paired with lenalidomide showed a statistically significant improvement over standard care in patients with relapsed …
A single dose of the lysergide orally disintegrating tablet achieved statistically significant MADRS improvement at six weeks compared …
Amtagvi becomes the first tumour-infiltrating lymphocyte therapy approved in Australia for advanced melanoma, entering a market with the …
BlueRock Therapeutics reports that a single transplant of dopaminergic progenitors derived from pluripotent stem cells produced durable reductions …
The RMAT-designated GABAergic interneuron cell therapy for drug-resistant mesial temporal lobe epilepsy demonstrated sustained seizure control in updated …
Arvinas’ vepdegestrant (VEPPANU) demonstrated a 43% reduction in risk of disease progression versus fulvestrant in the pivotal VERITAC-2 …
Four-year open-label extension data for zorevunersen reinforce the antisense oligonucleotide’s disease-modifying potential in SCN1A-linked epilepsy, as the pivotal …
The allogeneic GABAergic interneuron cell therapy reported durable seizure suppression beyond 13 months in drug-resistant mesial temporal lobe …
Already a subscriber? Log in